UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041029
Receipt number R000046856
Scientific Title Actual condition survey for the patients with type 2 diabetes mellitus and examination of both predictive and exacerbating factors for nonalcoholic fatty liver disease and arteriosclerotic disease in type 2 diabetes mellitus
Date of disclosure of the study information 2020/07/10
Last modified on 2020/07/08 00:30:46

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Actual condition survey for the patients with type 2 diabetes mellitus and examination of both predictive and exacerbating factors for nonalcoholic fatty liver disease and arteriosclerotic disease in type 2 diabetes mellitus

Acronym

Examination of actual condition and predictive factor for NAFLD and arteriosclerotic disease

Scientific Title

Actual condition survey for the patients with type 2 diabetes mellitus and examination of both predictive and exacerbating factors for nonalcoholic fatty liver disease and arteriosclerotic disease in type 2 diabetes mellitus

Scientific Title:Acronym

Examination of actual condition and predictive factor for NAFLD and arteriosclerotic disease

Region

Japan


Condition

Condition

Nonalcoholic fatty liver disease (NAFLD)
Nonalcoholic steatohepatitis (NASH)
Type 2 diabetes mellitus
Cardiovascular disease
Arteriosclerotic disease

Classification by specialty

Medicine in general Hepato-biliary-pancreatic medicine Cardiology
Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to clarify the relationship between the pathophysiology of NAFLD and arteriosclerotic disease among type 2 diabetes mellitus by conducting actual condition survey of nonalcoholic fatty liver disease (NAFLD) and arteriosclerotic disease. Next, we will explore other factor associated with arteriosclerotic disease. Finally, we will investigate the predictive factor for onset and progression of NAFLD and arteriosclerotic disease, and further examine the infuluence of NAFLD and arteriosclerotic disease on prognosis, and onset and progression of metabolic disease and cancer.

Basic objectives2

Others

Basic objectives -Others

usefulness

Trial characteristics_1

Exploratory

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

1. Examine the relationship between NAFLD and arteriosclerotic disease.
2. Evaluate the correlation between NAFLD related factor and arteriosclerotic change.
3. Compare the risk factor for atherosclerosis between NAFLD and non-NAFLD patients.
4. Explore the factor associated with onset and progress of arteriosclerotic change.
5. Explore the factor associated with onset and progress of NAFLD.
6. Investigate the influence of the NAFLD and arteriosclerotic change on onset of metabolic diseases, cancer, and prognosis.

Key secondary outcomes

(1) Explore the factors associated with atherosclerotic changes.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Outpatients from April 1998 to July 2024 who visited the facilities which is related with Ehime University Graduate School of Gastroenterology, Endocrine and Metabolism.
2.Male and female over eighteen years of age
3.Patients who have already been or newly diagnosed with diabetes.
4.Patients, who are in regular visits, agree to participate in this survey by written consent
5.Patients, who have not attended a hospital, do not have no intention of not participating by opt-out.

Key exclusion criteria

1. Patients with pregnancy or lactation
2. Patients judged for inappropriate by doctor

Target sample size

4000


Research contact person

Name of lead principal investigator

1st name Teruki
Middle name
Last name Miyake

Organization

Ehime University Graduate School of Medicine

Division name

Department of Gastroenterology and Metabology

Zip code

7910295

Address

Shitsukawa, Toon City, Ehime, Japan

TEL

0899605308

Email

teruki-ygc@umin.ac.jp


Public contact

Name of contact person

1st name Teruki
Middle name
Last name Miyake

Organization

Ehime University Graduate School of Medicine

Division name

Department of Gastroenterology and Metabology

Zip code

7910295

Address

Shitsukawa, Toon City, Ehime, Japan

TEL

+81899605308

Homepage URL


Email

teruki-ygc@umin.ac.jp


Sponsor or person

Institute

Ehime University

Institute

Department

Personal name



Funding Source

Organization

Ehime University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor

Yawatahama General City Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Committee of Ehime University Hospital

Address

Shitsukawa, Toon City, Ehime, Japan

Tel

+81899605914

Email

rinri@m.ehime-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 07 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2019 Year 09 Month 24 Day

Date of IRB

2019 Year 09 Month 24 Day

Anticipated trial start date

2020 Year 07 Month 08 Day

Last follow-up date

2024 Year 07 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

The aim of this study is to clarify the relationship between the pathophysiology of NAFLD and arteriosclerotic disease among type 2 diabetes mellitus by conducting actual condition survey of nonalcoholic fatty liver disease (NAFLD) and arteriosclerotic disease. Next, we will explore other factor associated with arteriosclerotic disease. Finally, we will investigate the predictive factor for onset and progression of NAFLD and arteriosclerotic disease, and further examine the infuluence of NAFLD and arteriosclerotic disease on prognosis, and onset and progression of metabolic disease and cancer.


Management information

Registered date

2020 Year 07 Month 08 Day

Last modified on

2020 Year 07 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046856


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name